MAIA Stock Price, MAIA Biotechnology, Inc. Quote, Chart

Market Summary

USD3.27+0.15

Market Closed

4.81%

MAIA Alerts

2 major insider buys recently.

MAIA Stock Price

View Fullscreen

MAIA RSI Chart

MAIA Valuation

Market Cap

71.4M

Price/Earnings (Trailing)

-3.01

Price/Free Cashflow

-5.37

MAIA Price/Earnings (Trailing)

MAIA Profitability

Return on Equity

411.51%

Return on Assets

-272.18%

Free Cashflow Yield

-18.62%

MAIA Fundamentals

MAIA Earnings

Earnings (TTM)

-23.7M

Earnings Growth (Yr)

-95.96%

Earnings Growth (Qtr)

-28.94%

Breaking Down MAIA Revenue

Last 7 days

6.2%

Last 30 days

65.1%

Last 90 days

109.6%

How does MAIA drawdown profile look like?

MAIA Financial Health

Current Ratio

1.77

MAIA Investor Care

Shares Dilution (1Y)

60.26%

Diluted EPS (TTM)

-1.58

Tracking the Latest Insider Buys and Sells of MAIA Biotechnology, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 25, 2024	smith stan	bought	299,409	2.03	147,492	-
Apr 25, 2024	louie ngar yee	bought	39,919	2.03	19,665	-
Mar 14, 2024	luput cristian	bought	81,059	1.17	69,282	-
Mar 14, 2024	louie ngar yee	bought	200,000	1.17	170,940	-
Mar 14, 2024	guerrero ramiro	bought	8,105	1.17	6,928	-
Mar 14, 2024	chaouki steven m	bought	40,530	1.17	34,641	-
Mar 14, 2024	smith stan	bought	200,000	1.17	170,940	-
May 18, 2023	guerrero ramiro	bought	2,964	2.47	1,200	-
May 15, 2023	luput cristian	bought	7,890	2.63	3,000	-
Apr 28, 2023	vitoc vlad	bought	10,000	2.5	4,000	chief executive officer

Which funds bought or sold MAIA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	55,143	55,143	-%
May 15, 2024	STATE STREET CORP	unchanged	-	21,939	46,860	-%
May 15, 2024	MORGAN STANLEY	added	98.14	16,248	22,209	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-9.00	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-152,697,000	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	57.62	8,258	12,463	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-39.63	11,971	100,540	-%
May 15, 2024	Royal Bank of Canada	reduced	-81.08	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-58.68	-14,995	52,248	-%
May 14, 2024	NORTHERN TRUST CORP	unchanged	-	20,882	44,601	-%

Are Funds Buying or Selling MAIA?

Are funds buying MAIA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MAIA

No. of Funds

MAIA Alerts

2 major insider buys recently.

Recent SEC filings of MAIA Biotechnology, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	424B5	Prospectus Filed
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 23, 2024	8-K	Current Report

Peers (Alternatives to MAIA Biotechnology, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MAIA Biotechnology, Inc. News

Latest updates

MAIA Biotechnology, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	15.2%	8,716	7,567	7,001	10,269	9,074	12,022	14,783	9,760	10,543	11,327	747
Current Assets	15.0%	8,700	7,564	6,633	9,776	8,334	11,808	14,780	8,610	-	10,672	747
Cash Equivalents	15.7%	8,271	7,151	6,105	9,146	7,586	10,951	14,064	8,150	10,293	10,574	663
Liabilities	104.3%	14,481	7,089	4,253	3,394	3,991	3,514	2,672	3,098	2,622	2,146	2,363
Current Liabilities	-0.6%	4,908	4,937	4,150	3,273	3,766	3,269	2,456	3,098	-	2,146	1,694
Shareholder's Equity	-1307.3%	-5,764	478	2,748	6,874	5,083	8,508	12,111	6,662	9,014	9,181	-
Retained Earnings	-12.6%	-72,047	-63,980	-57,723	-52,847	-48,324	-44,207	-40,061	-35,157	-	-28,437	-15,934
Additional Paid-In Capital	2.9%	66,311	64,472	60,514	59,747	53,432	52,730	52,223	41,823	-	37,618	12,600
Shares Outstanding	17.8%	20,003	16,986	13,761	13,648	10,996	10,956	8,714	8,197	7,752	7,585	4,434
Float	-	-	-	-	22,484	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Cashflow From Operations	10.2%	-3,586	-3,992	-3,157	-2,560	-3,360	-2,949	-4,319	-2,019	-2,807	-1,607	-1,311	-	-
Share Based Compensation	-74.3%	350	1,362	571	619	538	489	532	585	713	614	779	-	-
Cashflow From Financing	-6.1%	4,717	5,025	126	-	-	-192	10,259	-120	2,531	1,229	5,483	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MAIA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development expenses	$ 2,320,742	$ 2,195,991
General and administrative expenses	1,628,134	1,988,259
Total operating expenses	3,948,876	4,184,250
Loss from operations	(3,948,876)	(4,184,250)
Other (expense) income:
Interest expense		(5,147)
Interest income	44,118	336
Australian research and development incentives	18,601	51,243
Change in fair value of warrant liability	(4,181,298)	20,942
Other income, net	(4,118,579)	67,374
Net loss	(8,067,455)	(4,116,876)
Net loss attributable to MAIA Biotechnology, Inc. shareholders	$ (8,067,455)	$ (4,116,876)
Net loss per share
Net loss per share basic	$ (0.46)	$ (0.38)
Net loss per share diluted	$ (0.46)	$ (0.38)
Weighted average common shares outstanding basic	17,601,407	10,977,054
Weighted average common shares outstanding diluted	17,601,407	10,977,054

MAIA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 8,271,449	$ 7,150,695
Prepaid expenses and other current assets	272,583	268,677
Australia research and development incentives receivable	155,969	144,680
Total current assets	8,700,001	7,564,052
Deferred offering costs	13,235	0
Other assets	2,800	2,800
Total assets	8,716,036	7,566,852
Current liabilities:
Accounts payable	1,872,502	1,638,546
Accrued expenses	3,035,265	3,298,607
Total current liabilities	4,907,767	4,937,153
Long term liabilities:
Warrant liability	9,573,197	2,152,188
Total liabilities	14,480,964	7,089,341
Commitments and contingencies (Note 7)
Stockholders' equity (deficit)
Preferred stock, $0.0001 par value, 30,000,000 shares authorized at March 31, 2024 and December 31, 2023, 0 shares issued and outstanding
Common stock, $0.0001 par value, 70,000,000 shares authorized at March 31, 2024 and December 31, 2023, 20,581,469 and 16,986,254 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2,059	1,699
Additional paid-in capital	66,310,691	64,472,249
Accumulated deficit	(72,047,632)	(63,980,177)
Accumulated other comprehensive loss	(30,046)	(16,260)
Total stockholders' equity (deficit)	(5,764,928)	477,511
Total liabilities and stockholders' equity (deficit)	$ 8,716,036	$ 7,566,852

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.

CEO	Dr. Vlad Vitoc M.B.A., M.D.
WEBSITE	MAIABiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	18

MAIA Biotechnology, Inc. Frequently Asked Questions

What is the ticker symbol for MAIA Biotechnology, Inc.? What does MAIA stand for in stocks?

MAIA is the stock ticker symbol of MAIA Biotechnology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MAIA Biotechnology, Inc. (MAIA)?

As of Fri May 17 2024, market cap of MAIA Biotechnology, Inc. is 71.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MAIA stock?

You can check MAIA's fair value in chart for subscribers.

What is the fair value of MAIA stock?

You can check MAIA's fair value in chart for subscribers. The fair value of MAIA Biotechnology, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MAIA Biotechnology, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MAIA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MAIA Biotechnology, Inc. a good stock to buy?

The fair value guage provides a quick view whether MAIA is over valued or under valued. Whether MAIA Biotechnology, Inc. is cheap or expensive depends on the assumptions which impact MAIA Biotechnology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MAIA.